Immusoft raises $3M Series B tranche, names Sean Ainsworth CEO as Hurler’s Syndrome therapy nears human trials
Immusoft raised $3 million as the first tranche of its Series B to advance a Hurler’s Syndrome gene therapy into human trials, and appointed veteran biotech executive Sean Ainsworth as CEO while founder Matthew Scholz becomes CTO.